Tempus offers a broad range of contract and traditional clinical options using our CAP-accredited CLIA-certified next-generation sequencing lab.

  • Tempus|xT

    Targeted panel of 648 genes

  • Tempus|xE

    Whole exome of ~20,000 genes

  • Tempus|xF

    Liquid biopsy panel of 105 genes

Tempus has additional capabilities including single-cell sequencing and genome-wide liquid biopsy profiling.
For these capabilities, please send your inquiries to research@tempus.com.


Learn more about our sequencing capabilities


We provide key clinical findings for microsatellite instability (MSI) status, tumor mutational burden (TMB), and when applicable, PD-L1 IHC results. We also report insights for research related to therapeutic resistance risk and RNA expression of immunotherapy targets (e.g., PD-L1, CTLA-4), and biologically-relevant findings such as neoantigen prediction, HLA genotyping, and tumor immune infiltration.


Accelerating how researchers explore, evaluate, and design cutting-edge cancer treatments

At the Tempus|M modeling lab, a state of the art in-vitro facility, we use patient-derived biological modeling to understand the consequence of cancer genome alterations on growth, therapeutic sensitivity, and immune evasion.

We leverage the genomic- and clinically-annotated organoid library through a suite of experimental capabilities on our customized platforms spanning high-throughput screening, high-content imaging, next-generation and single-cell sequencing, effector cell co-culture experiments, and standard histopathology capabilities. We work in close collaboration with our partners to offer a bespoke set of services in order to maximize value that may lead to further inquiry with other Tempus resources such as real-world and molecular data.

Organoid development

Each organoid model represents a primary culture of a given patient’s tumor from fresh or viably cryopreserved surgical resections or core biopsy. After extensive molecular and histologic characterization, organoids are expanded, experimentally phenotyped, and cryopreserved. The end result is a rich multi-faceted dataset suitable for discovery efforts by our academic and industry partners.

Tempus block Image


Tumor organoids are characterized by the Tempus|xT 648 gene-panel and whole transcriptome analysis including copy number prediction. An informatics pipeline is used to compare mutational recapitulation between the organoid models and the originating patient’s tumor. Organoids are also annotated for genome-wide analyses such as MSI and Homologous Recombination Deficiency (HRD).

Tempus block Image


Tumor organoids can be treated with established small molecules, antibody drug conjugates and effector cell systems such as CAR-T or CAR-NK and the tumor organoid response is evaluated with a robust and reproducible high content and machine learning based assay.

Tempus block Image


Advanced image recognition technology

Our highly-automated research image analysis is optimized around advanced pattern recognition and data characterization. The program is designed to quantify various tumor characteristics in a non-invasive and objective way. Our complex machine-learning algorithms are constantly running in the background, which allows us to improve the speed and accuracy of our insights engine in real time.

By combining our web-based pathology and radiology platforms with state-of-the-art image analysis tools, we enable pathologists and researchers to access, share, and analyze images anywhere at anytime.

Request a demo

Big Background image

Clinical Trial and Research Offerings


The Priority Study is an observational study of participants with comprehensive genomic profiling. The goal of the study is to create a robust data set of health information about cancer patients who receive comprehensive genomic profiling in order to facilitate future novel precision medicine research. The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. This study is a master study and will include sub-protocols for specific tumor or molecular cohorts. The master protocol provides a data collection platform that permits the collection of a common set of data elements across participants in the Study at all participating Institutions.

Investigators can collaborate with others at their own institution as well as with investigators at other participating sites to address key research questions that are pertinent to their patient populations. By participating in the Priority Study, investigators and sites get access to technology to bring actionable data that can be used to find answers within patient populations.

To learn more, please email prioritystudy@tempus.com.


The TIME Trial™ Program brings biomarker-driven clinical trials closer to patients across a just-in-time network of industry sponsors and providers with deep research expertise.

Tempus generates, organizes, and analyzes extensive amounts of data to support providers in identifying relevant and actionable clinical trials for their patients. Our TIME Trial™ Program enables providers in the network to have access to a portfolio of clinical trials and expand treatment options for their patients. All participants in the TIME Trial™ Program utilize a pre-packaged clinical trial agreement, a pre-negotiated budget, a central IRB, and a team of dedicated Tempus research liaisons to shorten starting a new trial from months into weeks.

Learn more about the TIME Trial Program.

Learn more about partnering with Tempus to accelerate research initiatives.

Contact Us